A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

NCT06032546 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

163

Enrollment

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Human Immuno-deficiency Virus (HIV) Disease

Interventions

DRUG: Budigalimab
DRUG: Placebo for Budigalimab
DRUG: ABBV-382
DRUG: Placebo for ABBV-382
DRUG: Budigalimab

Sponsor

AbbVie